NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

A very positive DCVax-L article in Frontiers, dated 8/16/2021, tiltled: Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells states the following:

Furthermore, a DC-based vaccine (DCVax®-L), where DCs are pulsed with tumor cell lysate and injected into the patient, is used for medication of newly diagnosed glioblastoma (NCT00045968). Phase I/II clinical trials determined the safety of the vaccine (Liau et al., 2018). 33% of patients with glioblastoma had a median OS of 48 months, 27% even achieved a median OS of 72 months in the long-term survival analysis, encouraging the use of DCVax®-L for glioblastoma therapy in the future

https://www.frontiersin.org/articles/10.3389/fcell.2021.695325/full